Neurology Today in 5 artwork

BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine

Neurology Today in 5

English - April 04, 2024 03:00 - 4 minutes - 6.02 MB - ★★★★★ - 14 ratings
Science Health & Fitness Medicine neurology Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: SARS-CoV-2 and dopamine neurons, valproate risks for men, neurologists on locum tenens
Next Episode: ME/CFS and long COVID; negative outcomes for ALS drug; donanemab

Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.